Ongoing Investigation into Protalix BioTherapeutics, Inc. (PLX): Contact Levi & Korsinsky About Potential Fraud
NEW YORK, NY / ACCESS Newswire / October 23, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Protalix BioTherapeutics, Inc. ("Protalix BioTherapeutics, Inc.") (NYSE:PLX) concerning possible violations of federal securities laws. On October 17, 2025, Protalix and Chiesi Global Rare Diseases, Protalix’s partner in "the development, production and commercialization […]